Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Tenax Therapeutics, Inc.

Market Cap 707M 616M 571M 534M 1B 66.67B 1.01B 6.77B 2.62B 32.81B 2.65B 2.6B 114B P/E 2026 *
-7.93x
P/E 2027 * -8.5x
Enterprise Value 707M 616M 571M 534M 1B 66.67B 1.01B 6.77B 2.62B 32.81B 2.65B 2.6B 114B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.88%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day+1.10%
1 week+4.53%
Current month+1.10%
3 months-16.08%
6 months-8.40%
Current year-1.56%
1 week 11.11
Extreme 11.1119
12.28
1 month 10.25
Extreme 10.25
12.45
Current year 10.25
Extreme 10.25
18.38
1 year 5.62
Extreme 5.616
18.38
3 years 2.77
Extreme 2.77
61.2
5 years 2.77
Extreme 2.77
3,680
10 years 2.77
Extreme 2.77
88,640
Manager TitleAgeSince
Chief Executive Officer 52 14/07/2021
Director of Finance/CFO 58 11/05/2026
Chief Tech/Sci/R&D Officer - 21/01/2025
Director TitleAgeSince
Chairman 67 01/06/2021
Director/Board Member 76 25/02/2021
Director/Board Member 68 25/02/2021
Date Insider Type Main position Quantity % Market Cap.
05-11Other

Chief Financial Officer

0 0%
05-11Free

Chief Financial Officer

460,000 2.6748%
01-30Other

Controller/Auditor

50,000 0.8008%
Change 5-day change 1-year change 3-year change Capi.($)
+1.10%+4.53%+107.25%-48.63% 707M
+1.44%+1.71%-10.98%-6.19% 43.13B
+3.31%+5.93%+310.97%+534.70% 34.65B
+2.84%+2.14%+9.34%+41.02% 30.03B
-1.70%-7.54%+8.43%-21.94% 28B
-1.90%-1.56%+10.24%+21.21% 24.45B
-0.14%+5.86% - - 14.34B
+0.68%-1.53%+48.76%+104.27% 13.14B
-0.57%-2.43%+5.08%+4.79% 12.53B
-0.26%+1.15%+98.13%+80.47% 12.25B
Average +0.48%+1.84%+65.25%+78.86% 21.32B
Weighted average by Cap. +0.78%+1.31%+65.62%+109.50%

Financials

2026 *2027 *
Net sales - -
Net income -81.07M -70.69M -65.47M -61.29M -115M -7.65B -116M -777M -301M -3.77B -304M -298M -13.07B -94.93M -82.77M -76.66M -71.76M -135M -8.96B -135M -909M -352M -4.41B -356M -349M -15.31B
Net Debt - -
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
18/06/26 12.00 $ +1.10% 2,691,091
17/06/26 11.87 $ +4.77% 1,280,545
16/06/26 11.33 $ -1.90% 795,067
15/06/26 11.55 $ +0.61% 760,046
12/06/26 11.48 $ +6.99% 1,767,803
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
12.00USD
Average target price
34.00USD
Spread / Average Target
+183.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TENX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!